1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
PanGen Biotech, Inc.

PanGen Biotech, Inc.

KKRX:222110
4,705.00
KRW
-80.00
(-1.67%)
79.82EPS
60.31P/E
65.18BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
603.09
632.22
175.09
251.64
590.01
298.85
642.43
776.7
609.01
684.44
1,274.96
1,007.58
1,002.84
Basic EPS, GAAP
-376
-447
-614
-744
-481
-927
-452
-324
-421
-420
82
154
80.08
Free Cash Flow per Basic Share
-613.64
-540.18
-935.63
-377.95
-693.46
-466.83
-565.86
-469.65
-396.88
-368.24
227.03
-41.12
-256.78
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,372.85
1,096.8
3,901.91
3,256.03
2,794.17
1,911.1
1,473.91
1,976.95
1,612.67
1,176.85
1,931.18
2,217.56
2,278.74
Tangible Book Value per Share
678.2
125.63
3,036.85
2,490.2
2,015.75
1,271.25
901.86
1,517.62
1,219.07
787.49
1,667.02
1,992.89
2,072.71
Basic Weighted Avg Shares
6
6
8
9
10
10
10
10
11
11
12
13
14
Sales/Revenue/Turnover
3,400
3,731
1,461
2,373
5,679
2,881
6,191
7,936
6,501
7,315
14,673
13,417
14,177
Operating Margin (%)
-59.42
-54.21
-497.49
-164
-53.59
-276.89
-59.77
-41.44
-70.62
-57.76
6.95
11.23
1.66
Depreciation Expense
975
1,055
1,142
786
848
1,654
1,568
1,532
1,603
1,597
1,468
1,465
1,533
Net Income, GAAP
-2,120
-2,638
-5,125
-7,016
-4,630
-8,938
-4,356
-3,310
-4,494
-4,489
944
2,051
1,132
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.97
0.8
0.26
Profit Margin (%)
-62.35
-70.7
-350.69
-295.67
-81.52
-310.19
-70.36
-41.71
-69.13
-61.36
6.43
15.28
7.99
Working Capital
-1,525
-4,191
17,514
14,613
13,439
6,700
4,001
11,267
7,447
4,132
17,869
20,394
21,308
LT Debt
350
- -
- -
- -
- -
- -
- -
5
4
2
- -
- -
6
Total Equity
8,212
6,561
35,307
31,309
26,941
18,426
14,211
21,098
17,219
12,566
24,909
29,924
30,750
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.81
5.31
0.77
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.18
7.76
4.11
Return on Common Equity (%)
- -
-35.71
-24.48
-21.06
-15.9
-39.4
-26.69
-18.75
-23.46
-30.14
5.04
7.48
3.76

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
962
1,003
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
75,568
69,495
65,177

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
23,140
23,801
23,800
Cash, Cash Equivalents & STI
13,804
12,707
12,052
Accounts Receivable, Net
1,574
2,963
3,077
Inventories
7,240
7,420
8,247
Total Current Liabilities
2,746
2,746
2,492
Payables & Accruals
- -
- -
- -
ST Debt
962
1,003
1
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
47.98%
24.28%
20.14%
Free Cash Flow
-15.16%
-63.63%
-120.96%
Net Income, GAAP
14.68%
1.58%
117.3%
Sales/Revenue/Turnover
32.11%
22.93%
-8.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,475
2,268
4,595
4,335
14,673
2025
3,441
3,485
4,013
2,477
13,417
2026
3,732
3,956
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
18
104
-39.68
82
2025
57
67
39.42
-7.57
154
2026
55.62
-3
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jae-Seung Yoon
Full Time Employees
78
Sector
Health technology
Industry
Biotechnology
Address
Suwon-si South Korea
IPO Date
Mar 11, 2016
Website
pangen.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
PanGen Biotech, Inc. is a South Korea-based biopharmaceutical company specializing in the development, manufacture, and commercialization of biosimilars, recombinant protein therapeutics, and biomanufacturing contract development and manufacturing organization (CDMO) services. Founded in 1999 and headquartered in Seongnam, South Korea, the company operates research and cGMP manufacturing facilities, serving biopharmaceutical clients and patients across South Korea, Southeast Asia, the Middle East, and other international markets. The company's primary products and services include; PDA10 (epoetin alfa), a recombinant erythropoietin (EPO) biosimilar indicated for the treatment of anemia associated with chronic renal failure and chemotherapy; PDR005, a recombinant coagulation Factor VIII product candidate developed for the management of Hemophilia A; PDR001, a recombinant granulocyte colony-stimulating factor (G-CSF) candidate for chemotherapy-induced neutropenia; customized cell line development services utilizing its proprietary PanGen CHO-TECH Chinese Hamster Ovary expression platform; upstream bioprocess development and scale-up fermentation; downstream purification and formulation optimization; bioanalytical method development and stability testing; and cGMP-compliant contract manufacturing of recombinant therapeutic proteins for clinical and commercial supply. In recent strategic developments, PanGen Biotech underwent a significant ownership and governance transition following its acquisition by South Korean healthcare conglomerate Huons Co., Ltd., which became the company's largest shareholder to integrate PanGen's biologics research and CDMO capabilities with Huons' broader global pharmaceutical infrastructure. In addition, the company continues to broaden the commercial distribution of its erythropoietin biosimilar PDA10 through long-term strategic partnerships, notably with Malaysia-based Duopharma Biotech Berhad for commercialization across ASEAN markets, while expanding its third-party CDMO pipeline and bioprocess manufacturing capacities.